PSMA PET/CT w wykrywaniu przerzutów i wznowy nowotworu gruczołu krokowego
Słowa kluczowe:
gruczolakorak, PET-PSMAStreszczenie
Rak prostaty jest bardzo częstym nowotworem wśród mężczyzn. Średnio 48 mężczyzn każdego dnia w Polsce dowiaduje się, że jest chorych. Niezmiernie ważne jest, aby choroba była diagnozowana na wczesnym etapie, ponieważ tylko wtedy pacjent ma największe szanse na przeżycie i powrót do zdrowia. Diagnostyka schorzenia obejmuje głównie pomiar wartości parametru PSA, badanie per rectum oraz obrazowanie. Badania obrazowe wykonywane są podczas podejrzenia nowotworu lub kontrolnie po leczeniu tej choroby. Nie są one niestety w stanie wykryć raka we wczesnym stadium, co przekłada się na gorsze rokowanie pacjentów.Nadzieję dla tych mężczyzn może stanowić nowa technika tomografii komputerowej PET/CT, która dzięki wykorzystaniu specyficznego dla prostaty markera o wysokiej czułości i swoistości, możliwe jest wczesne wykrycie raka.
Bibliografia
Tu X, Zhang C, Liu Z, et al. The Role of Ga-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Intermediate/High Risk Patients With Prostate Cancer: A Diagnostic Meta-Analysis. Front Oncol. 2020;10:1365.
Zattoni F, Nehra A, Murphy CR, et al. Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy. Eur Urol Focus. 2016;2(5):522-531.
Krajowy Rejestr Nowotworów
Combes AD, Palma CA, Calopedos R, et al. PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. Diagnostics (Basel). 2022;12(11). doi:10.3390/diagnostics12112594
Rahbar K, Afshar-Oromieh A, Bögemann M, et al. F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. Eur J Nucl Med Mol Imaging. 2018;45(8):1329-1334.
Kesch C, Kratochwil C, Mier W, Kopka K, Giesel FL. Ga or F for Prostate Cancer Imaging? J Nucl Med. 2017;58(5):687-688.
Ardies PJ, Gykiere P, Goethals L, De Mey J, De Geeter F, Everaert H. PSMA Uptake in Mediastinal Sarcoidosis. Clin Nucl Med. 2017;42(4):303-305.
Wang X, Wen Q, Zhang H, Ji B. Head-to-Head Comparison of Ga-PSMA-11 PET/CT and Multiparametric MRI for Pelvic Lymph Node Staging Prior to Radical Prostatectomy in Patients With Intermediate to High-Risk Prostate Cancer: A Meta-Analysis. Front Oncol. 2021;11:737989.
Emmett L, Buteau J, Papa N, et al. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol. 2021;80(6):682-689.
Satapathy S, Singh H, Kumar R, Mittal BR. Diagnostic Accuracy of Ga-PSMA PET/CT for Initial Detection in Patients With Suspected Prostate Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2021;216(3):599-607.
Kwon T, Jeong IG, You D, Hong JH, Ahn H, Kim CS. Prevalence and clinical significance of incidental (18)F-fluoro-2-deoxyglucose uptake in prostate. Korean J Urol. 2015;56(4):288-294.
Leyten GHJM, Hessels D, Smit FP, et al. Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clin Cancer Res. 2015;21(13):3061-3070.
Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Netw. 2021;19(2):134-143.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.
van Kalmthout LWM, Lam MGEH, de Keizer B, et al. Impact of external cooling with icepacks on Ga-PSMA uptake in salivary glands. EJNMMI Res. 2018;8(1):56.
Dong L, Su Y, Zhu Y, et al. The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. J Nucl Med. 2022;63(2):248-252.
Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76-85.
Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2019;75(6):967-987.
Shin D, Ha S, O JH, et al. A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial. Cancers . 2022;14(24). doi:10.3390/cancers14246225
van der Gaag S, Bartelink IH, Vis AN, Burchell GL, Oprea-Lager DE, Hendrikse H. Pharmacological Optimization of PSMA-Based Radioligand Therapy. Biomedicines. 2022;10(12). doi:10.3390/biomedicines10123020
Lauri C, Chiurchioni L, Russo VM, Zannini L, Signore A. PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications? J Clin Med Res. 2022;11(21). doi:10.3390/jcm11216590
Giesel FL, Will L, Lawal I, et al. Intraindividual Comparison of F-PSMA-1007 and F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. J Nucl Med. 2018;59(7):1076-1080.
Kesch C, Vinsensia M, Radtke JP, et al. Intraindividual Comparison of F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. J Nucl Med. 2017;58(11):1805-1810.
Paddubny K, Freitag MT, Kratochwil C, et al. Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy. Clin Genitourin Cancer. 2018;16(2):103-105.
Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467-479.
Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med. 2015;56(8):1185-1190.
Giesel FL, Will L, Paddubny K, et al. [18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty. Clin Genitourin Cancer. 2018;16(2):111-113.
Giesel FL, Knorr K, Spohn F, et al. Detection Efficacy of F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J Nucl Med. 2019;60(3):362-368.
Kopka K, Benešová M, Bařinka C, Haberkorn U, Babich J. Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. J Nucl Med. 2017;58(Suppl 2):17S - 26S.
Giesel FL, Cardinale J, Schäfer M, et al. (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43(10):1929-1930.
Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55-62.
Cardinale J, Schäfer M, Benešová M, et al. Preclinical Evaluation of F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. J Nucl Med. 2017;58(3):425-431.
Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2015;56(5):668-674.
Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486-495.
Opublikowane
8 sierpnia 2023
Prawa autorskie (c) 2023 Karolina Sas; Kamila Tokarczyk, Damian Zieliński, Kinga Dworak, Natalia Trędota
Licencja
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
